Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

NKTR

Nektar Therapeutics

Jan 06 • 04:00PM ET

42.97

-1.50 -3.37 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI VXF SCHA XPH VHT PRFZ IHE LFSC SURI ITOT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.94	Insider Own	1.48%	Shs Outstand	20.34M	Perf Week	0.56%
Market Cap	874.08M	Forward P/E	-	EPS next Y	-9.79	Insider Trans	-8.83%	Shs Float	20.04M	Perf Month	-25.52%
Enterprise Value	770.95M	PEG	-	EPS next Q	-2.41	Inst Own	70.39%	Short Float	9.62%	Perf Quarter	-28.30%
Income	-120.74M	P/S	13.96	EPS this Y	-14.85%	Inst Trans	40.27%	Short Ratio	2.30	Perf Half Y	89.05%
Sales	62.60M	P/B	9.92	EPS next Y	2.00%	ROA	-39.63%	Short Interest	1.93M	Perf YTD	1.63%
Book/sh	4.33	P/C	3.23	EPS next 5Y	-8.99%	ROE	-180.24%	52W High	66.92 -35.79%	Perf Year	198.09%
Cash/sh	13.28	P/FCF	-	EPS past 3/5Y	41.29% 25.49%	ROIC	-52.50%	52W Low	0.43 9846.76%	Perf 3Y	30.21%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.15% -3.00%	Gross Margin	85.92%	Volatility	4.32% 6.85%	Perf 5Y	-84.30%
Dividend TTM	-	EV/Sales	12.32	EPS Y/Y TTM	36.87%	Oper. Margin	-217.83%	ATR (14)	3.17	Perf 10Y	-83.31%
Dividend Ex-Date	-	Quick Ratio	4.24	Sales Y/Y TTM	-32.79%	Profit Margin	-192.87%	RSI (14)	38.24	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	4.24	EPS Q/Q	29.43%	SMA20	-9.77%	Beta	-0.98	Target Price	114.43
Payout	-	Debt/Eq	1.96	Sales Q/Q	-51.13%	SMA50	-20.90%	Rel Volume	0.56	Prev Close	44.47
Employees	61	LT Debt/Eq	1.70	Earnings	Nov 06 AMC	SMA200	33.17%	Avg Volume	838.81K	Price	42.97
IPO	May 03, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.35% 17.26%	Trades		Volume	474,160	Change	-3.37%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-25	Initiated	Citigroup	Buy	$102
Jun-24-25	Reiterated	H.C. Wainwright	Buy	$6.50 → $120
Jun-24-25	Reiterated	BTIG Research	Buy	$60 → $100
Apr-11-25	Upgrade	Jefferies	Hold → Buy	$2
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform	$6
Jan-08-25	Initiated	B. Riley Securities	Buy	$4
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform

Show Previous Ratings

Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-21-25 07:31AM	Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) (Insider Monkey)
Dec-16-25 07:30AM	REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata (PR Newswire) -7.77%
06:24AM	Loading…
06:24AM	Nektar sees silver lining as autoimmune drug narrowly misses in alopecia study (BioPharma Dive)
Dec-15-25 06:00PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 (PR Newswire)
Dec-08-25 12:00PM	Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy (Zacks)
Dec-05-25 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-01-25 09:55AM	Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade (Zacks) -6.29%
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly) +8.85%
Nov-23-25 07:02AM	Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? (Insider Monkey)
Nov-20-25 06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool) -8.68%
Nov-13-25 09:55AM	Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect? (Zacks) -6.45%
Nov-08-25 05:45PM	New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
10:11AM	Loading…
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
12:07AM	Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Nov-06-25 05:55PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:06PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:00AM	Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -7.72%
Oct-30-25 06:00PM	Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire) +5.32%
10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 06:00PM	Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
09:55AM	Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High? (Zacks)
Oct-26-25 06:06AM	Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation (Insider Monkey)
Oct-22-25 08:00AM	Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Oct-13-25 08:37AM	This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street (Motley Fool) +5.63%
Oct-05-25 08:41AM	Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September (Motley Fool)
Sep-25-25 05:22AM	Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks) -7.81%
06:43PM	Loading…
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-18-25 05:34PM	Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today (Motley Fool) +15.06% -6.16%
12:23PM	EADV 25: Nektar presents data from AD candidate that sent stocks flying (Clinical Trials Arena)
08:45AM	Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 (PR Newswire)
Sep-09-25 07:00AM	Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 (PR Newswire) +9.56%
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks) +10.33%
Sep-05-25 01:32PM	Why Nektar Therapeutics Rippled Higher This Week (Motley Fool) +11.67%
Sep-03-25 07:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in September (PR Newswire) +26.02%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-08-25 06:15PM	Why Nektar Therapeutics Stock Popped 6% on Friday (Motley Fool) +6.02%
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
Aug-07-25 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:33PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-05-25 06:10PM	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-04-25 11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-31-25 06:00PM	Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets (PR Newswire) +5.90%
Jul-29-25 09:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata (PR Newswire)
01:31AM	Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin (Insider Monkey)
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
Jul-06-25 04:01AM	Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin (Insider Monkey)
Jul-03-25 07:00PM	Why Nektar Therapeutics Stock Dived by 3% Today (Motley Fool) -5.21%
Jul-02-25 04:15PM	Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jul-01-25 07:17AM	Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire)
Jun-30-25 04:02PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-28-25 08:15AM	Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher? (MarketBeat)
Jun-25-25 06:45PM	Why Nektar Therapeutics Stock Was Red-Hot Today (Motley Fool) +19.10%
12:20PM	Wainwright sets over $100 target for Nektar on paradigm-shifting data (TipRanks)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 04:23PM	Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment (Investor's Business Daily) +156.29%
10:54AM	Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results (Investopedia)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
09:07AM	Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam (Investor's Business Daily)
07:30AM	REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Jun-23-25 04:30PM	Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 (PR Newswire) +12.10%
May-13-25 05:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (PR Newswire)
May-09-25 02:29PM	Q1 2025 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:46AM	Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... (GuruFocus.com)
May-08-25 06:25PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:19PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire)
May-07-25 05:20PM	Nektar Therapeutics Q1 2025 Earnings Preview (Seeking Alpha) -5.67%
May-01-25 06:00PM	Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-11-25 02:29PM	Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 (GuruFocus.com) +23.76%
11:30AM	Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? (Zacks)
Mar-22-25 06:57PM	Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil (Insider Monkey)
Mar-20-25 06:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-14-25 07:33AM	Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) (Zacks) +9.98%
Mar-13-25 12:06PM	Q4 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Mar-12-25 08:30PM	Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:00PM	Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates (Zacks)
06:12PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-05-25 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-27-25 10:59AM	Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata (Clinical Trials Arena)
Feb-26-25 07:00AM	Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata (PR Newswire) -10.38%
Feb-24-25 07:00AM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th (PR Newswire) -9.35%
07:00AM	Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus (PR Newswire)
Feb-10-25 07:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Feb-07-25 09:35AM	Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround (Zacks)
Jan-31-25 09:55AM	Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-10-25 07:00AM	Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire) -9.65%
Jan-07-25 09:24AM	Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-07-24 12:00PM	Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting (PR Newswire)
Nov-18-24 03:30PM	Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence (PR Newswire)

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	Nov 25 '25	Sale	54.28	1,157	62,802	18,971	Nov 25 08:30 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 25 '25	Sale	54.28	630	34,196	21,585	Nov 25 08:29 PM
ROBIN HOWARD W	President & CEO	Nov 25 '25	Sale	54.28	2,207	119,796	54,245	Nov 25 08:28 PM
ROBIN HOWARD W	Officer	Nov 25 '25	Proposed Sale	58.82	2,207	129,812		Nov 25 03:35 PM
Wilson Mark Andrew	Officer	Nov 25 '25	Proposed Sale	58.82	630	37,056		Nov 25 03:32 PM
Zalevsky Jonathan	Officer	Nov 25 '25	Proposed Sale	58.82	1,157	68,053		Nov 25 03:28 PM
ROBIN HOWARD W	President & CEO	Sep 09 '25	Sale	46.69	6,666	311,214	49,342	Sep 11 09:01 PM
ROBIN HOWARD W	Officer	Sep 09 '25	Proposed Sale	46.69	6,666	311,205		Sep 09 04:57 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 04 '25	Sale	33.52	1,721	57,693	17,462	Sep 08 08:32 PM
ROBIN HOWARD W	President & CEO	Sep 05 '25	Sale	38.53	6,666	256,851	56,008	Sep 08 08:31 PM
ROBIN HOWARD W	President & CEO	Sep 04 '25	Sale	33.70	5,166	174,108	62,674	Sep 08 08:31 PM
ROBIN HOWARD W	Officer	Sep 05 '25	Proposed Sale	38.53	6,666	256,838		Sep 05 04:37 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 02 '25	Sale	30.10	485	14,598	19,183	Sep 04 09:02 PM
ROBIN HOWARD W	President & CEO	Sep 02 '25	Sale	30.16	1,500	45,240	67,840	Sep 04 09:01 PM
ROBIN HOWARD W	Officer	Sep 04 '25	Proposed Sale	33.70	5,166	174,119		Sep 04 05:06 PM
Zalevsky Jonathan	Officer	Sep 04 '25	Proposed Sale	33.52	1,721	57,688		Sep 04 04:19 PM
Zalevsky Jonathan	Officer	Sep 02 '25	Proposed Sale	30.10	485	14,600		Sep 02 04:45 PM
ROBIN HOWARD W	Officer	Sep 02 '25	Proposed Sale	30.16	1,500	45,244		Sep 02 04:42 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '25	Sale	26.59	725	19,278	19,668	Aug 21 09:05 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '25	Sale	26.59	676	17,975	20,312	Aug 21 09:04 PM
ROBIN HOWARD W	President & CEO	Aug 19 '25	Sale	26.59	1,573	41,826	69,340	Aug 21 09:03 PM
ROBIN HOWARD W	Officer	Aug 19 '25	Proposed Sale	26.59	1,573	41,826		Aug 19 03:24 PM
Wilson Mark Andrew	Officer	Aug 19 '25	Proposed Sale	26.59	676	17,975		Aug 19 03:24 PM
Zalevsky Jonathan	Officer	Aug 19 '25	Proposed Sale	26.59	725	19,278		Aug 19 03:20 PM
Zalevsky Jonathan	Chief R&D Officer	May 19 '25	Sale	0.67	10,712	7,177	305,892	May 21 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	May 19 '25	Sale	0.67	9,996	6,697	314,296	May 21 08:07 PM
ROBIN HOWARD W	President & CEO	May 19 '25	Sale	0.67	23,208	15,549	1,063,693	May 21 08:07 PM
Zalevsky Jonathan	Officer	May 19 '25	Proposed Sale	0.67	10,712	7,191		May 19 03:49 PM
Wilson Mark Andrew	Officer	May 19 '25	Proposed Sale	0.67	9,996	6,710		May 19 03:44 PM
ROBIN HOWARD W	Officer	May 19 '25	Proposed Sale	0.67	23,208	15,580		May 19 03:40 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 19 '25	Sale	1.01	10,300	10,403	316,604	Feb 21 06:07 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 19 '25	Sale	1.01	11,040	11,150	324,292	Feb 21 06:06 PM
ROBIN HOWARD W	President & CEO	Feb 19 '25	Sale	1.01	23,774	24,012	1,086,901	Feb 21 06:04 PM
Wilson Mark Andrew	Officer	Feb 19 '25	Proposed Sale	1.01	11,040	11,137		Feb 19 03:27 PM
ROBIN HOWARD W	Officer	Feb 19 '25	Proposed Sale	1.01	23,774	23,983		Feb 19 03:21 PM
Zalevsky Jonathan	Officer	Feb 19 '25	Proposed Sale	1.01	10,300	10,391		Feb 19 03:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKTR

Nektar Therapeutics

Upgrade your FINVIZ experience